bernsteinjoshi, any finer guesstimates on milestones / regulatory events besides what RDHL has announced already? Seems like next stockmoving catalyst is BEKINDA gastro in early 4Q'15. Don't think EU MAA approvals will pop the stock. Thinking of selling as stock is unlikely to hold onto gains & likely to see $17 handle.
Jason you're the best pied piper I know.
Radio City Music Hall
1260 Avenue of the Americas, New York, NY 10020
Show up early - don't get crushed by the crowd!
Sentiment: Strong Buy
GIZMO, where did you see CTIX listed among top5 pharmas using $ efficiently? wud like to see the list. thx.
For starters...2.5mm/yr paying the top 5 officers (according to Co Profile on Yahoo) and what do they have to show in the last 5 years? failure after failure
Lurker, you seriously shouldn't be investing in biotech stocks as you don't understand the basics of the approval process and to compound it you have your britches in a knot with all the hyperventilating despite b-joshi's comprehensive answer. Maybe you should be investing in indexes and etf's only. Good luck. By the way, they don't make meds with the objective of feeding investor ROI's. med development is strictly for serving the patient community.
Last Friday and then again today. first pile-driven to 36c only to be brought back to 40c and above at the close by equal countermeasure. these hedge fundies have nothing better to do these days.
My 2c on p3 outcomes - H.p is a slam dunk, GE may have a good chance but Chron's is a really tough indication to conquer. So it's a good thing the way the readouts are sequenced.
Why does Roth estimate the value of RHB-105 at $5/sh to the co. or 50mm if the market for it is 1.5bn and RHB-105 has exclusivity till 2034??? There is currently no direct SOC for H. Pylori infection. Doesn't add up.